Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 1, 2015

BioPharm International

  • BioPharm International-03-01-2015
  • Volume 28
  • Issue 3

Polyethylene Biocontainer Increases Customizability

Meissner’s TepoFlex is a polyethylene biocontainer designed for secure handling and it is part of the One-Touch single-use systems portfolio.

Meissner’s TepoFlex is a polyethylene biocontainer designed for secure handling and it is part of the One-Touch single-use systems portfolio. Available in standard assembly designs of 50 mL–1000 L, the biocontainers can be fitted with customized tube lengths, connectors, and end fittings.

To fit existing rigid outer containers and biomanufacturing systems, custom biocontainers can be designed. The biocontainers, which serve applications from process development through production, are designed with the same materials throughout the entire portfolio to streamline scale-up efforts when ordering new parts.
Meissner Filtration Products
 

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.